Literature DB >> 23493345

Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.

Marlinda Adham1, Astrid E Greijer, Sandra A W M Verkuijlen, Hedy Juwana, Sabine Fleig, Lisnawati Rachmadi, Octavia Malik, A N Kurniawan, Averdi Roezin, Soehartati Gondhowiardjo, Djumhana Atmakusumah, Servi J C Stevens, Bambang Hermani, I Bing Tan, Jaap M Middeldorp.   

Abstract

PURPOSE: Nasopharyngeal carcinoma (NPC) is consistently associated with Epstein-Barr virus (EBV) and highly prevalent in Indonesia. EBV-DNA load can be used for early diagnosis and may have prognostic value. In this study, EBV-DNA load was evaluated in minimal invasive nasopharyngeal (NP) brushings and whole blood for initial diagnosis and therapy assessment against the standard-of-care diagnosis by biopsy with EBV-RISH and standard EBV-IgA serology. EXPERIMENTAL
DESIGN: NP brushings and blood samples were collected from 289 consecutive ENT patients suspected of NPCs and 53 local healthy controls. EBV-DNA load was quantified by real-time PCR and serology by peptide-based EBV-IgA ELISA. Tissue biopsies were examined by routine histochemistry and by EBER RNA in situ hybridization.
RESULTS: Repeated NP brushing was well tolerated by patients and revealed high viral load in the 228 NPC cases at diagnosis than 61 non-NPC cancer cases and healthy controls (P < 0.001). The diagnostic value of EBV-DNA load in blood and EBV-IgA serology was inferior to the NP brush results. The level of EBV-DNA load in brushes of patients with NPC was not related to T, N, or M stage, whereas elevated EBV-DNA load in blood correlated with N and M stage. EBV-DNA levels in brushings and whole blood showed a significant reduction at 2 months after treatment (P = 0.001 and P = 0.005, respectively), which was not reflected in EBV-IgA serology.
CONCLUSIONS: NP brush sampling combined with EBV-DNA load analysis is a minimal invasive and well-tolerated diagnostic procedure, suited for initial diagnosis and follow-up monitoring of NPCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23493345     DOI: 10.1158/1078-0432.CCR-12-2897

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Authors:  Sharon D Stoker; Maarten A Wildeman; Zlata Novalic; Renske Fles; Vincent van der Noort; Remco de Bree; Weibel W Braunius; Guido B van den Broek; Bas Kreike; Kenneth W Kross; Hedy Juwana; Octavia Ramayanti; Sandra A W M Verkuijlen; Jan Paul de Boer; Astrid E Greijer; Jaap M Middeldorp; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-01       Impact factor: 2.503

2.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

3.  Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma.

Authors:  Fei-Peng Zhao; Xiong Liu; Xiao-Mei Chen; Juan Lu; Bo-Long Yu; Wen-Dong Tian; L U Wang; Xia Xu; Hao-Ran Huang; Meng-Wen Zhang; Gang Li; Xiang-Ping Li
Journal:  Oncol Lett       Date:  2015-08-24       Impact factor: 2.967

4.  The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.

Authors:  Caiyun He; Xinjun Huang; Xuan Su; Tao Tang; Xiao Zhang; Jiangjun Ma; Xiang Guo; Xing Lv
Journal:  Cancer Biol Ther       Date:  2017-01-25       Impact factor: 4.742

5.  Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients.

Authors:  Cosphiadi Irawan; Andhika Rachman; Puji Rahman; Arif Mansjoer
Journal:  J Cancer Epidemiol       Date:  2021-10-30

6.  Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma.

Authors:  Meng Chen; Li Yin; Jing Wu; Jia-Jia Gu; Xue-Song Jiang; De-Jun Wang; Dan Zong; Chang Guo; Huan-Feng Zhu; Jian-Feng Wu; Xia He; Wen-Jie Guo
Journal:  Biomed Res Int       Date:  2015-01-31       Impact factor: 3.411

7.  Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.

Authors:  Xiao-Hui Zheng; Li-Xia Lu; Xi-Zhao Li; Wei-Hua Jia
Journal:  Cancer Sci       Date:  2015-07-14       Impact factor: 6.716

8.  Chick Chorioallantoic Membrane Assay: A 3D Animal Model for Study of Human Nasopharyngeal Carcinoma.

Authors:  Xue Xiao; Xiaoying Zhou; Huixin Ming; Jinyan Zhang; Guangwu Huang; Zhe Zhang; Ping Li
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

9.  Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers.

Authors:  Zeyi Deng; Takayuki Uehara; Hiroyuki Maeda; Masahiro Hasegawa; Sen Matayoshi; Asanori Kiyuna; Shinya Agena; Xiaoli Pan; Chunlin Zhang; Yukashi Yamashita; Minqiang Xie; Mikio Suzuki
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

Review 10.  Current treatment options for local residual nasopharyngeal carcinoma.

Authors:  S D Stoker; J N A van Diessen; J P de Boer; B Karakullukcu; C R Leemans; I B Tan
Journal:  Curr Treat Options Oncol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.